CiLostAzol for pReventIon of Recurrent sTroke in Africa

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,100

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

December 31, 2027

Conditions
Stroke
Interventions
DRUG

Cilostazol 100 mg

Patients allocated to the experimental arm will receive 100mg of cilostazol tablets taken twice daily. To mitigate side-effects in both treatment arms, all patients will begin one tablet daily and titrate to the full dose (one tablet twice daily) after 2 weeks. Participants will stay on the full dose of cilostazol for the remainder of the study.

Trial Locations (1)

Unknown

Kwame Nkrumah University of Science & Technology, Kumasi

All Listed Sponsors
lead

Northern California Institute of Research and Education

OTHER